The use of copper-lowering therapy with tetrathiomolybdate in medicine

被引：42

作者：

Brewer, George J. ^{[1
,2
]}

机构：

[1] Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2009年 / 18卷 / 01期

关键词：

alzheimer's disease therapy; anticopper therapy; autoimmune disease therapy; cancer therapy; fibrotic disease therapy; inflammatory disease therapy; tetrathiomolybdate; Wilson's disease therapy; NEUROLOGICALLY AFFECTED PATIENTS; PHASE-II TRIAL; SQUAMOUS-CELL CARCINOMA; AMMONIUM TETRATHIOMOLYBDATE; WILSONS-DISEASE; ALZHEIMERS-DISEASE; INITIAL THERAPY; MOUSE MODEL; FOLLOW-UP; PULMONARY-FIBROSIS;

D O I：

10.1517/13543780802621859

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Background: Tetrathioimolybdate (TM), an anticopper drug, has been developed for the neurologic presentation of Wilson's disease. In animal models, lowering copper levels with TM produces antifibrotic, anti-inflammatory, antiautoimmune, and anticancer effects, thought to be due to inhibition of many cytokines that are dependent on available copper for their activity. Clinical testing has been done relatively extensively in Wilson's disease and advanced cancers, but remains in its infancy in other diseases. Objectives: To review current preclinical and clinical studies done with TM, and our current knowledge of TM efficacy and toxicity. Methods: We have reviewed the last 10 years of literature on TM therapy. Results/conclusion: TM has excellent efficacy and acceptable toxicity for the initial treatment of neurologically presenting Wilson's disease. TM has excellent efficacy in animal models of fibrotic, inflammatory, autoimmune, and neoplastic diseases, as well as Alzheimer's disease models.

引用

页码：89 / 97

页数：9

共 72 条

[1]

Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ [J].